Publications by authors named "Filippo De Marinis"

100Publications

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

N Engl J Med 2020 Sep 19. Epub 2020 Sep 19.

From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2027071DOI Listing
September 2020

Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.

N Engl J Med 2020 09;383(10):944-957

From the Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne and University of Cologne, Cologne (J.W.), Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, Heidelberg (M.T.), the Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen (T.R.O.), and Hämato-Onkologie Hamburg, Hamburg (E.L.) - all in Germany; the National Hospital Organization Kyushu Cancer Center, Fukuoka (T.S.), Aichi Cancer Center, Nagoya (T.H.), the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.), the Department of Respiratory Medicine, Okayama University Hospital, Okayama (K.O.), and the National Kyushu Cancer Center, Fukuoka (R.T.) - all in Japan; the National Cancer Center, Gyeonggi-do (J.-Y.H.), and the Department of Internal Medicine, Seoul National University Hospital, Seoul (T.-M.K.) - both in South Korea; the Hospital Clinic of Barcelona (N.R.), Translational Genomic and Targeted Therapeutics in Solid Tumors (IDIBAPS) (N.R.), and Vall d'Hebron University Hospital-Vall d'Hebron Institute of Oncology (E.F.), Barcelona; David Geffen School of Medicine at UCLA, Los Angeles (E.B.G.); the University of Groningen and University Medical Center Groningen, Groningen (H.J.M.G.), Erasmus MC Cancer Institute, Rotterdam (M.J.), and the Netherlands Cancer Institute, Amsterdam (E.F.S.) - all in the Netherlands; the National Cancer Centre Singapore, Singapore (D.S.W.T.); St. Petersburg Pavlov State Medical University, St. Petersburg, Russia (S.V.O.); University Hospital of Lyon-Sud, Lyon (P.-J.S.), and Novartis Pharma, Rueil-Malmaison (S.L.M.) - both in France; the Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium (J.V.); the Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna (M.H.); the Thoracic Oncology Division, European Institute of Oncology, IRCCS, Milan (F.M.); Novartis Pharmaceuticals, East Hanover, NJ (A.R., M.G.); Novartis Pharma, Basel, Switzerland (M.W.-L., M.A.); and Novartis Institutes for BioMedical Research, Cambridge (B.S., O.A.B., X.C.), and Massachusetts General Hospital, Boston (R.S.H.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2002787DOI Listing
September 2020

Reply.

Clin Lung Cancer 2020 Sep 25;21(5):e415-e416. Epub 2020 Feb 25.

Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.02.009DOI Listing
September 2020

Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.

Cancer 2020 Jun 10;126(11):2594-2596. Epub 2020 Mar 10.

Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32810DOI Listing
June 2020

Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.

Lung Cancer 2020 04 25;142:70-79. Epub 2020 Feb 25.

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.02.017DOI Listing
April 2020

Lung cancer surgery in oligometastatic patients: outcome and survival.

Eur J Cardiothorac Surg 2020 Jun;57(6):1173-1180

Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejcts/ezaa005DOI Listing
June 2020

Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.

Transl Lung Cancer Res 2019 Dec;8(Suppl 4):S334-S338

Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2019.06.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987339PMC
December 2019

Brain metastases in EGFR-positive non-small cell lung cancer: the way to the becomes less winding.

Ann Transl Med 2019 Jul;7(Suppl 3):S80

Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan 20141, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.04.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685842PMC
July 2019

Understanding the Mechanisms of Resistance in -Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.

Int J Mol Sci 2019 Aug 14;20(16). Epub 2019 Aug 14.

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20163951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720634PMC
August 2019

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

J Clin Oncol 2019 08 17;37(22):1863-1867. Epub 2019 Apr 17.

1European Institute of Oncology, IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/JCO.18.02118
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02118DOI Listing
August 2019

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients.

J Clin Med 2019 Jan 18;8(1). Epub 2019 Jan 18.

Unit of Histopathology and Molecular Diagnostics, Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8010112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352111PMC
January 2019

Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterfly.

Pulmonology 2018 Nov - Dec;24(6):321-322

Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pulmoe.2018.12.001DOI Listing
September 2019

Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets.

Chin Clin Oncol 2019 Oct 15;8(S1):S1. Epub 2018 Oct 15.

Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.09.03DOI Listing
October 2019

Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

Clin Lung Cancer 2019 03 24;20(2):97-106.e1. Epub 2018 Oct 24.

Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy; University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.005DOI Listing
March 2019

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.

Immunotherapy 2018 09;10(12):1041-1045

Division of Pathology & Laboratory Medicine, European Institute of Oncology, Via Ripamonti 451, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0027DOI Listing
September 2018

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.

Transl Lung Cancer Res 2018 Apr;7(Suppl 2):S100-S102

Division of Thoracic Oncology, European Institute of Oncology, IEO, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.02.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943218PMC
April 2018

Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.

Arch Pathol Lab Med 2018 Apr;142(4):465-473

From the Divisions of Pathology (Drs Guerini-Rocco, Casadio, Midolo De Luca, and Barberis, and Mr Vacirca), Thoracic Oncology (Drs Passaro and de Marinis), and Thoracic Surgery (Dr Guarize), European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0158-RADOI Listing
April 2018

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.

Stem Cells 2018 05 5;36(5):633-640. Epub 2018 Feb 5.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2787DOI Listing
May 2018

Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?

Crit Rev Oncol Hematol 2017 Nov 19;119:30-39. Epub 2017 Sep 19.

Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.09.007DOI Listing
November 2017

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.

Am J Respir Crit Care Med 2017 Nov;196(10):1349-1350

2 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201705-0875IMDOI Listing
November 2017

Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.

Semin Thorac Cardiovasc Surg 2017 Summer;29(2):233-241. Epub 2017 Feb 24.

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy; Department of Hematology and Oncology (DIPO), University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semtcvs.2017.02.001DOI Listing
September 2017

Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma.

Eur J Cardiothorac Surg 2017 Nov;52(5):975-981

Division of Thoracic Surgery, European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejcts/ezx122DOI Listing
November 2017

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.

Pharmacol Res 2017 03 12;117:406-415. Epub 2017 Jan 12.

Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2017.01.003DOI Listing
March 2017

Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.

Semin Thorac Cardiovasc Surg 2016 Summer;28(2):593-602. Epub 2015 Dec 10.

Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semtcvs.2015.12.001DOI Listing
June 2017

[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]

Recenti Prog Med 2016 Dec;107(12):634-640

Divisione di Oncologia Toracica, Istituto Europeo di Oncologia, Milano.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1701/2502.26230DOI Listing
December 2016

Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.

Expert Rev Clin Pharmacol 2016 Oct 20;9(10):1283-1288. Epub 2016 Sep 20.

a Division of Thoracic Oncology , European Institute of Oncology , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2016.1233059DOI Listing
October 2016

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Lung Cancer 2016 09 14;99:31-7. Epub 2016 Jun 14.

Thoracic Oncology Division, Istituto Europeo di Oncologia (IEO), Via Ripamonti 435, 20141 Milan, Italy, Italy; Formerly Department of Thoracic Oncology, 1st Pulmonary Oncological Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.06.008DOI Listing
September 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

Expert Rev Anticancer Ther 2016 08 15;16(8):799-801. Epub 2016 Jul 15.

a Division of Thoracic Oncology , European Institute of Oncology , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2016.1210007DOI Listing
August 2016

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

Clin Lung Cancer 2016 09 4;17(5):e179-e183. Epub 2016 Jun 4.

Thoracic Division, Medical Oncology Department, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.004DOI Listing
September 2016

[Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances].

Recenti Prog Med 2016 Apr;107(4):186-92

Divisione di Oncologia Toracica, Istituto Europeo di Oncologia, Milano.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1701/2218.23930DOI Listing
April 2016

Cellular and molecular biology of small cell lung cancer: an overview.

Transl Lung Cancer Res 2016 Feb;5(1):2-15

1 Instituto Oncolόgico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Division of Thoracic Oncology, European Institute of Oncology (IEO), Milan, Italy ; 4 Pangaea Biotech, Barcelona, Spain ; 5 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 7 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2016.01.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758976PMC
February 2016

The role of extended pulmonary metastasectomy.

J Thorac Oncol 2015 Jun;10(6):924-9

*Division of Thoracic Surgery, European Institute of Oncology, University of Milan, Milan, Italy; †Division of Epidemiology and Biostatistics, ‡Division Clinical Oncology, European Institute of Oncology, Milan, Italy; and §School of Medicine, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000547DOI Listing
June 2015

PET/CT characterization of non-small-cell lung cancer heterogeneity.

Nucl Med Commun 2015 May;36(5):411-3

aDivision of Nuclear Medicine bThoracic Oncology Division, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000270DOI Listing
May 2015